Literature DB >> 22330985

Comparison of 2D and 3D imaging and treatment planning for postoperative vaginal apex high-dose rate brachytherapy for endometrial cancer.

James K Russo1, Kent E Armeson, Susan Richardson.   

Abstract

PURPOSE: To evaluate bladder and rectal doses using two-dimensional (2D) and 3D treatment planning for vaginal cuff high-dose rate (HDR) in endometrial cancer. METHODS AND MATERIALS: Ninety-one consecutive patients treated between 2000 and 2007 were evaluated. Seventy-one and 20 patients underwent 2D and 3D planning, respectively. Each patient received six fractions prescribed at 0.5 cm to the superior 3 cm of the vagina. International Commission on Radiation Units and Measurements (ICRU) doses were calculated for 2D patients. Maximum and 2-cc doses were calculated for 3D patients. Organ doses were normalized to prescription dose.
RESULTS: Bladder maximum doses were 178% of ICRU doses (p < 0.0001). Two-cubic centimeter doses were no different than ICRU doses (p = 0.22). Two-cubic centimeter doses were 59% of maximum doses (p < 0.0001). Rectal maximum doses were 137% of ICRU doses (p < 0.0001). Two-cubic centimeter doses were 87% of ICRU doses (p < 0.0001). Two-cubic centimeter doses were 64% of maximum doses (p < 0.0001). Using the first 1, 2, 3, 4 or 5 fractions, we predicted the final bladder dose to within 10% for 44%, 59%, 83%, 82%, and 89% of patients by using the ICRU dose, and for 45%, 55%, 80%, 85%, and 85% of patients by using the maximum dose, and for 37%, 68%, 79%, 79%, and 84% of patients by using the 2-cc dose. Using the first 1, 2, 3, 4 or 5 fractions, we predicted the final rectal dose to within 10% for 100%, 100%, 100%, 100%, and 100% of patients by using the ICRU dose, and for 60%, 65%, 70%, 75%, and 75% of patients by using the maximum dose, and for 68%, 95%, 84%, 84%, and 84% of patients by using the 2-cc dose.
CONCLUSIONS: Doses to organs at risk vary depending on the calculation method. In some cases, final dose accuracy appears to plateau after the third fraction, indicating that simulation and planning may not be necessary in all fractions. A clinically relevant level of accuracy should be determined and further research conducted to address this issue.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22330985     DOI: 10.1016/j.ijrobp.2011.11.029

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

Review 1.  Vaginal cuff brachytherapy in endometrial cancer - a technically easy treatment?

Authors:  Sebastià Sabater; Ignacio Andres; Veronica Lopez-Honrubia; Roberto Berenguer; Marimar Sevillano; Esther Jimenez-Jimenez; Angeles Rovirosa; Meritxell Arenas
Journal:  Cancer Manag Res       Date:  2017-08-09       Impact factor: 3.989

2.  A comparison between 2D and 3D planning of high-dose-rate vaginal cuff brachytherapy in patients with stage I-II endometrial cancer using cobalt-60.

Authors:  Farnaz Amouzegar Hashemi; Sepideh Mansouri; Mahdi Aghili; Ebrahim Esmati; Mohammad Babaei; Arefeh Saeedian; Sepand Moalej; Ramin Jaberi
Journal:  J Contemp Brachytherapy       Date:  2021-10-25

3.  Volumetric (3D) bladder dose parameters are more reproducible than point (2D) dose parameters in vaginal vault high-dose-rate brachytherapy.

Authors:  Lucas Gomes Sapienza; Adriana Flosi; Antonio Aiza; Antonio Cassio de Assis Pellizzon; Rubens Chojniak; Glauco Baiocchi
Journal:  Sci Rep       Date:  2016-06-14       Impact factor: 4.379

4.  Bladder and rectum dose estimations on digitized radiographs for vaginal brachytherapy after hysterectomy.

Authors:  Winson Zhang; Sundershan K Bhatia; Wenqing Sun; Joseph M Modrick; Yusung Kim
Journal:  J Appl Clin Med Phys       Date:  2014-11-08       Impact factor: 2.102

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.